Related Experiment Video
Updated: Jun 5, 2026
08:43
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
Sequential whole bladder photodynamic therapy treatments: A preclinical study
1Department of Urology, West Virginia University, Morgantown, WV, USA; Veterans Administration Medical Center, Clarksburg, WV, USA.
Urologic Oncology
|January 14, 2011
Summary
Sequential whole bladder photodynamic therapy (WBPDT) with low-dose Photofrin® is safe for bladder function. While a second treatment caused temporary bladder capacity loss, three treatments showed no persistent effects, supporting clinical investigation.
Area of Science:
- Urology
- Oncology
- Photodynamic Therapy
Background:
- Sequential whole bladder photodynamic therapy (WBPDT) may offer improved safety and tumor control.
- Potential cumulative effects on bladder function require investigation.
Purpose of the Study:
- To determine the safety of sequential WBPDT treatments in a preclinical model.
- To evaluate the impact of repeated low-dose WBPDT on bladder capacity and function.
Main Methods:
- Six female dogs received one WBPDT treatment (1.5 mg/kg Photofrin®, 15 J/cm² light).
- Four dogs received a second treatment, and three dogs received three treatments.
- Bladder function assessed via cystoscopy and cystometry; histopathology analyzed post-treatment.
Main Results:
- Single WBPDT caused minimal bladder capacity loss.
- Second WBPDT led to significant, persistent bladder capacity loss (17% at 12 weeks).
- Three WBPDT treatments resulted in temporary capacity loss with full recovery by 12 weeks; minimal muscle injury observed.
Conclusions:
- Sequential low-dose WBPDT (Photofrin®) is generally safe for bladder function.
- The second sequential treatment warrants careful consideration due to persistent capacity loss.
- Low-dose WBPDT is recommended for further clinical investigation.
